“CBD offers the benefits without the buzz”
— New York Times
CBD is a natural dietary supplement that has been shown to reduce inflammation in the body. Reducing inflammation is key to eliminating pain, stress, and general discomfort in the body, and has been shown to significantly reduce the risk of cancer, cognitive impairment, and many other deadly or debilitating diseases.
Scientific and clinical research suggest that CBD has a variety of additional benefits related to its naturally therapeutic properties "including anticonvulsive, sedative, hypnotic, antipsychotic, antiinflammatory and neuroprotective properties."
-National Center for Biotechnology Information, 2009
Cannabidiol (CBD) is extracted from hemp stalks, but is not a marijuana product. It is non psychoactive, meaning that it is safe, non-toxic, and therefore a very appealing option for people looking for safe, natural relief from a wide variety of conditions.
We can point you toward significant scientific and anecdotal evidence which furthers the idea that CBD may be effective in helping to treat a wide variety of medical issues, some of which is shown in our Testimonial Archive.
Further evidence suggests that CBD has demonstrable neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States Institute of Health and elsewhere around the globe.
For more information, please speak with your doctor or visit our FAQ page.
Read more about the medical benefits of CBD in The Journal of Clinical Pharmacology: Cannabidiol: An Overview of Some Pharmacological Aspects.
Sources: Alberto Mantovani, Paola Allavena, Antonio Sica & Frances Balkwill. "Cancer-related inflammation" Nature volume 454, pages 436–444 (24 July 2008). First Published . https://www.nature.com/articles/nature07205  Deans, Christopher; Wigmore, Stephen J. "Systemic inflammation, cachexia and prognosis in patients with cancer" Current Opinion in Clinical Nutrition and Metabolic Care: May 2005 - Volume 8 - Issue 3 - p 265–269 doi: 10.1097/01.mco.0000165004.93707.88